• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T

by MM360 Staff | Dec 20, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma

by MM360 Staff | Dec 20, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Pancreatic cancer treatment atebimetinib set for Phase 3 trial

by Marisa Wexler, MS | Dec 19, 2025 | Myeloma News

Immuneering is preparing to launch a Phase 3 clinical trial to test its experimental therapy, atebimetinib, in people with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company recently received positive feedback from the U.S....

Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells

by MM360 Staff | Dec 19, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

1st trial participant receives Alpha DaRT radiation therapy for glioblastoma

by Marisa Wexler, MS | Dec 18, 2025 | Myeloma News

The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The clinical trial (NCT06910306), sponsored by Alpha DaRT’s developer, Alpha Tau Medical, is expected to enroll...

by MM360 Staff | Dec 18, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
  • CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT